OSCROscar Health, Inc.

Oscar Health, Inc. (NYSE: OSCR) | Price: $30.97 | Today's Change: -6.65%

---

What Happened

Oscar Health filed an 8-K with the SEC on November 5, 2026 (Items 2.02 and 9.01), disclosing its financial results for the third quarter of fiscal year 2026. The company reported total revenues of $8.90 billion for the quarter, alongside a net loss of $90.54 million, or $0.35 per share (basic and diluted). Operating losses came in at $62.61 million, underscoring ongoing pressure on the company's cost structure even as the top line reflects the scale of its insurance premium volumes.

---

Why It Matters

For investors, the key concern in this print is the combination of a widening net loss and a meaningful operating loss in a quarter where total revenues approached $8.9 billion. The divergence between headline revenues and profitability is stark — revenue from contracts with customers (excluding assessed tax) was reported at just $19.63 million, which alongside the large premium-driven top line signals that Oscar's core service and fee-based revenues remain a small fraction of total receipts. The $0.35 per share loss reflects persistent unit-economics challenges that the company has been navigating as it scales. The stock's sharp decline of 6.65% on the day of this report suggests the market found the results disappointing relative to expectations.

---

Analysis

Oscar Health's Q3 FY2026 numbers present a mixed picture. The sheer scale of revenues — nearly $8.9 billion — demonstrates that Oscar has built a meaningfully large insurance book, but the operating loss of $62.6 million makes clear that medical cost ratios and administrative expenses continue to weigh heavily on the bottom line. The gap between operating loss ($62.6M) and net loss ($90.5M) also points to meaningful below-the-line charges — interest expense or similar items — amplifying the headline deficit.

What to watch going forward:

• Medical Loss Ratio (MLR) trends: The critical driver of profitability for any health insurer; any commentary on Q4 or full-year MLR guidance will be pivotal.
• Membership growth versus cost discipline: Oscar's growth story requires that scale eventually translates into margin improvement — the Q3 results will raise scrutiny on the pace of that transition.
• Full-year guidance reaffirmation or revision: Any update to FY2026 guidance in the accompanying earnings call will be closely watched, particularly given the size of the quarterly loss.

This filing follows StockWatch's existing initiating coverage on Oscar Health. The Q3 results introduce near-term uncertainty and will likely prompt a reassessment of the trajectory toward profitability that underpins the investment thesis.

---

Disclaimer

This report is a news and informational summary based solely on data extracted from Oscar Health's official SEC filing dated November 5, 2026, and publicly available market data. It does not constitute investment advice, a solicitation to buy or sell any security, or an equity research recommendation. No rating or price target is assigned or implied. Investors should conduct their own due diligence and consult a qualified financial adviser before making any investment decisions.

Existing Coverage

StockWatch has full coverage on OSCR, published 2026-09-09. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-05. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1568651/000156865126000082/oscr-20261105.htm